Skip to main content

SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY.

Publication ,  Journal Article
Grewal, DS; Jaffe, GJ; Keenan, RT
Published in: Retin Cases Brief Rep
September 1, 2021

PURPOSE: To demonstrate a rapid improvement of recalcitrant cystoid macular edema (CME) and perivascular leakage, in a patient with non-paraneoplastic autoimmune retinopathy and autoimmune optic neuropathy after treatment with sarilumab, a human anti-interleukin-6 (IL-6) receptor antibody. METHODS: Observational case report. RESULTS: A 29-year-old woman was diagnosed with non-paraneoplastic autoimmune retinopathy and autoimmune optic neuropathy and followed over 1.5 years. She had recalcitrant CME despite local corticosteroid and immunosuppressive therapy that included azathioprine and adalimumab. Subcutaneous sarilumab was initiated at a dose of 200 mg every 2 weeks. Cystoid macular edema significantly decreased after two injections and resolved after four injections with associated improvement in visual acuity and significant improvement in perivascular leakage on fluorescein angiography. There was a sustained visual and anatomical improvement at 6 months along with mild improvement in electroretinogram responses. The patient tolerated the medication with no side effects. CONCLUSION: Management of CME in non-paraneoplastic autoimmune retinopathy is challenging, and long-term immunosuppression is often employed with varying degrees of success. The improvement in refractory CME and perivascular leakage in this case supports the potential role of an IL-6 inhibitor to treat CME associated with non-paraneoplastic autoimmune retinopathy suggesting the role.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Retin Cases Brief Rep

DOI

EISSN

1937-1578

Publication Date

September 1, 2021

Volume

15

Issue

5

Start / End Page

504 / 508

Location

United States

Related Subject Headings

  • Retinal Diseases
  • Receptors, Interleukin-6
  • Macular Edema
  • Humans
  • Female
  • Autoimmune Diseases
  • Antibodies, Monoclonal, Humanized
  • Adult
  • 3212 Ophthalmology and optometry
  • 1113 Opthalmology and Optometry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Grewal, D. S., Jaffe, G. J., & Keenan, R. T. (2021). SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. Retin Cases Brief Rep, 15(5), 504–508. https://doi.org/10.1097/ICB.0000000000000872
Grewal, Dilraj S., Glenn J. Jaffe, and Robert T. Keenan. “SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY.Retin Cases Brief Rep 15, no. 5 (September 1, 2021): 504–8. https://doi.org/10.1097/ICB.0000000000000872.
Grewal DS, Jaffe GJ, Keenan RT. SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. Retin Cases Brief Rep. 2021 Sep 1;15(5):504–8.
Grewal, Dilraj S., et al. “SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY.Retin Cases Brief Rep, vol. 15, no. 5, Sept. 2021, pp. 504–08. Pubmed, doi:10.1097/ICB.0000000000000872.
Grewal DS, Jaffe GJ, Keenan RT. SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. Retin Cases Brief Rep. 2021 Sep 1;15(5):504–508.

Published In

Retin Cases Brief Rep

DOI

EISSN

1937-1578

Publication Date

September 1, 2021

Volume

15

Issue

5

Start / End Page

504 / 508

Location

United States

Related Subject Headings

  • Retinal Diseases
  • Receptors, Interleukin-6
  • Macular Edema
  • Humans
  • Female
  • Autoimmune Diseases
  • Antibodies, Monoclonal, Humanized
  • Adult
  • 3212 Ophthalmology and optometry
  • 1113 Opthalmology and Optometry